Medicamen Biotech Ltd Share Price

430.15

Open ()
Turnover (lac)
Prev. Close ()
Day's Vol.(shares)
Detailed Quote

Corporate Action

Period From
Period To
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 20-May-2019 - -
MEDICAMEN BIOTECH LTD.-$has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2019 ,inter alia, to consider and approve MBL wish to inform you that, pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, May 30, 2019 at 11:30 am at Registered Office of the Company to inter alia consider and approve the following business(s): 1. Audited Financial Results of the Company for the quarter / year ended on March 31, 2019. 2. Recommend final dividend on equity shares of the Company for the Financial Year 2018-19. 3. Any other business with the permission of Chair. This is for your information and records. We wish to inform you that the Board of Directors of the Company at its meeting held today has inter alia:- 1. Approved the Audited Financial Statements of the Company for the financial year ended March 31, 2019 and the Audited Financial results for the quarter/year ended March 31, 2019. 2. Recommended a Dividend of Rs. 1 per equity share of Rs. 10/-each for the financial year ended March 31, 2019. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following: a) Statement showing the Audited Financial Results of the Company for the quarter/financial year ended March 31, 2019 as Annexure-A and b) Auditors Report on the Audited Financial Results as Annexure-B. The meeting of the Board of Directors commenced on 11.30 a.m. and concluded at 01.20 p.m. We wish to inform you that the Board of Directors of the Company at its meeting held today has inter alia:- 1. Approved the Audited Financial Statements of the Company for the financial year ended March 31, 2019 and the Audited Financial results for the quarter/year ended March 31, 2019. 2. Recommended a Dividend of Rs. 1 per equity share of Rs. 10/-each for the financial year ended March 31, 2019. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following: a) Statement showing the Audited Financial Results of the Company for the quarter/financial year ended March 31, 2019 as Annexure-A and b) Auditors Report on the Audited Financial Results as Annexure-B. The meeting of the Board of Directors commenced on 11.30 a.m. and concluded at 01.20 p.m. (As Per BSE Announcement Dated 30.05.2019)
Board Meeting - 21-May-2019 - -
In terms of Regulation 30 of SEBI Listing Regulations, 2015, we would like to inform your good office that the Board of the Directors of the Company in their meeting held today at 03.00 PM & Concluded at 03.30 PM has made preferential allotment of 5,16,600 equity shares of Rs. 10/- Each at an issue price of Rs. 485/- (including premium of Rs. 475/-) each to the person belonging to Promoter and Non Promoter group in accordance with chapter V of SEBI(ICDR) Regulations, 2018.
Board Meeting - 05-Apr-2019 - -
MEDICAMEN BIOTECH LTD.-$has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/04/2019 ,inter alia, to consider and approve A Meeting of the Board of Directors of the Company is scheduled to be held on Thursday the 11th day of April, 2019 at 11:30 a.m. at the Registered Office of the Company i.e. 1506, Chiranjiv Tower, 43. Nehru Place, New Delhi- 110019 to discuss and consider the matter as follows: 1. To issue Equity Shares on Preferential Allotment basis to the promoter and non-promoter group entities. 2. To adopt the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information 3. To call an Extra Ordinary General Meeting of the members to approve the preferential allotment. In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 (SEBI (LODR) Regulations), read with SEBI Circular dated September 9, 2015, we would like to inform you that Board of Directors of the Company in their meeting held on today i.e. Thursday, April 11, 2019, which was commenced at 11:30 AM and concluded at 03.30 PM. inter alia, approved the proposal for issuance of up to 6,00,000 Equity Shares of Rs. 10/- Each, on preferential basis, at an issue price of Rs. 485/- (Rupees Four Hundred and Eighty Five Only) [including a securities premium of Rs. 475/-each],to a promoter group and non promoter group/ Investors. For the aforesaid purpose Extraordinary General meeting of the company will be held on Monday, May 6, 2019 at 11.00 AM, at SP-1192 A & B Phase - IV, Industrial Area, Bhiwadi-301019 Distt. Alwar (Rajasthan). (As Per BSE Announcement Dated On 11/04/2019)
Board Meeting - 24-Jan-2019 - -
MEDICAMEN BIOTECH LTD.-$has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2019 ,inter alia, to consider and approve Medicamen Biotech Limited has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on Monday, 11/02/2019 inter alia to consider,approve and take on record of Un-audited Financial Results for the quarter ended on 31st December, 2018 subject to a limited review by Statutory Auditors. Public Notice published in the Newspapers viz. - Financial Express (English) and Jansatta (Hindi), in compliance with Regulation 47(1) of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, informing that the Meeting of the Board of Directors of the Company is scheduled to be held on Monday, 11th February, 2019, inter alia, to consider and approve and take on record of Un-audited Financial Statement of the Company for the Quarter ended on 31st December, 2018. We wish to inform you that pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at their meeting held today on 11 February 2019, inter alia, have considered and approved the following: 1. Un-Audited Financial Results for the quarter ended 31 December 2018. 2. Limited Review Report provided by Statutory Auditors on the Un-Audited Financial Results for the quarter ended 31 December 2018 of the Company. 3. Appointment of Dr Vimal Kumar Shrawat as an Additional Director (Non-Executive) of the Company. 4. Cessation of Mr. Klaus Snej Jensen from the post of Independent Director of the Company. 5. Appointment of Ms. Sangeeta Bishnoi as an Additional Director (Independent) of the Company. The Board meeting commenced at 11.30 a.m. and concluded at 03.15 p.m. Kindly acknowledge receipt of the same. Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015, we wish to inform you that the Board of Directors of our Company in its meeting held today i.e. on February 11, 2019 had among other matters, considered and approved the following:- 1. Appointment of Dr Vimal Kumar Shrawat (DIN: 08274190) as as an Additional Director (Non-Executive) 2. Cessation of Mr. Klaus Snej Jensen (DIN: 07554059) from the post of Non-Executive-Independent Director 3. Appointment of Ms. Sangeeta Bishnoi (DIN: 08288998) as an Additional Director (Independent) This is for your information and record. (As Per BSE Announcement Dated On 11/02/2019) Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations , 2015, we are enclosing herewith copies of newspaper publication pertaining to the Un-audited Financial Results for the quarter ended 31st December, 2018, published in Financial Express (English) & Jansatta (Hindi) newspapers on 12.02.2019. (As Per BSE Announcement Dated On 12/02/2019)
Board Meeting - 24-Jan-2019 - -
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the Board of Directors at its meeting held today, i.e. January 24, 2019 has appointed Mr. Rajesh Kumar Chauhan (DIN: 08340413) as a Whole Time Director of the Company for a period of five years with immediate effect. This is for your information and record.
Board Meeting - 06-Nov-2018 - -
MEDICAMEN BIOTECH LTD.-$has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2018 ,inter alia, to consider and approve Medicamen Biotech Limited has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, 13/11/2018 inter alia to consider,approve and take on record of Un-audited Financial Results for the quarter and half year ended on 30th September, 2018 subject to a limited review by Statutory Auditors. We wish to inform you that pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at their meeting held today on 13 November 2018, inter alia, have considered and approved the following: 1. Un-Audited Financial Results for the quarter and half year ended 30 September 2018. 2. Limited Review Report provided by Statutory Auditors on the Un-Audited Financial Results for the quarter and half year ended 30 September 2018 of the Company. The Board meeting commenced at 11.00 a.m. and concluded at 12.30 p.m. Kindly acknowledge receipt of the same. (As Per BSE Announcement Dated on 13.11.2018)
Board Meeting - 17-Jul-2018 - -
Quarterly Results & Un-audited Financial Results;Approve draft Annual Report;Approve Re-classification of NIAM International Pvt Ltd We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results of the Company for the quarter ended on June 30, 2018. Further Board of Directors at their meeting approved the following resolutions: c) Approved draft Annual Report for the financial year 2017-18. d) Approved Re-classification of NIAM International Private Limited as non-promoter entity of the Company. e) An Investor Release dated 25th July, 2018 on the financial results is enclosed. f) Appointment of Mr. Pratap Singh Rawat as Chief Financial Officer & Key Managerial Personnel of the Company. (As Per BSE Announcement Dated On 25/07/2018)